- Home
- RVNC vs DBL Comparison
RVNC vs DBL Comparison
Compare RVNC & DBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVNC
- DBL
- Stock Information
- Founded
- RVNC 1999
- DBL 2011
- Country
- RVNC United States
- DBL United States
- Employees
- RVNC N/A
- DBL N/A
- Industry
- RVNC Biotechnology: Pharmaceutical Preparations
- DBL
- Sector
- RVNC Health Care
- DBL
- Exchange
- RVNC Nasdaq
- DBL Nasdaq
- Market Cap
- RVNC 320.5M
- DBL 284.1M
- IPO Year
- RVNC 2014
- DBL N/A
- Fundamental
- Price
- RVNC $3.09
- DBL $15.33
- Analyst Decision
- RVNC Hold
- DBL
- Analyst Count
- RVNC 9
- DBL 0
- Target Price
- RVNC $8.45
- DBL N/A
- AVG Volume (30 Days)
- RVNC 3.6M
- DBL 61.0K
- Earning Date
- RVNC 11-07-2024
- DBL 01-01-0001
- Dividend Yield
- RVNC N/A
- DBL 8.67%
- EPS Growth
- RVNC N/A
- DBL N/A
- EPS
- RVNC N/A
- DBL N/A
- Revenue
- RVNC $256,945,000.00
- DBL N/A
- Revenue This Year
- RVNC $11.28
- DBL N/A
- Revenue Next Year
- RVNC $27.21
- DBL N/A
- P/E Ratio
- RVNC N/A
- DBL N/A
- Revenue Growth
- RVNC 25.82
- DBL N/A
- 52 Week Low
- RVNC $2.30
- DBL $13.75
- 52 Week High
- RVNC $9.75
- DBL $15.70
- Technical
- Relative Strength Index (RSI)
- RVNC 33.47
- DBL 36.15
- Support Level
- RVNC $3.06
- DBL $15.42
- Resistance Level
- RVNC $3.09
- DBL $15.76
- Average True Range (ATR)
- RVNC 0.11
- DBL 0.12
- MACD
- RVNC 0.02
- DBL -0.02
- Stochastic Oscillator
- RVNC 6.90
- DBL 10.20
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.